Remove 2028 Remove Packaging Remove Vaccines
article thumbnail

STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more

STAT

This calls for celebration with a cup of stimulation, and we are opening a new package of pecan pie for the occasion. In a press release issued ahead of an investor meeting today, the company also said it plans to break even by 2028, when it expects it will reach annual sales of $6 billion. Sound familiar? Have a great day, everyone.

Packaging 140
article thumbnail

USP General Chapter —Glass revised

European Pharmaceutical Review

In response to supply chain challenges, including shortages of critical glass vials for products like COVID-19 vaccines and parenteral drugs, the Packaging and Distribution Expert Committee (PD EC) has made a significant revision of United States Pharmacopeia (USP) General Chapter <660>—Glass.

Packaging 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Future-proofing the pharma cold chain

Express Pharma

The COVID-19 pandemic also highlighted the vital role of the cold chain in ensuring patient safety during vaccine distribution. And, with India’s vaccine, biopharma, and clinical trials market projected to grow in double-digits, there will be an increasing demand for efficient cold chain facilities. per cent during 2022-2028.

Packaging 115
article thumbnail

16th edition of CPHI & PMEC India Expo to be held from November 28-30, 2023, at India Expo Centre, Greater Noida

Express Pharma

lakh crores) by 2028. Fette Compacting Machinery India, Ace Technologies & Packaging Systems, DPB Antibiotics, Lee Pharma, Omniscient Health, hcare, Venkata Narayana Active Ingredients, Unilab Chemicals and Pharmaceuticals, and many others. billion (Rs 8.5

Packaging 105
article thumbnail

Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from P-I/II Trial with PDC*lung01

PharmaShots

PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. These new results reinforce our differentiating data package for PDC*lung01.